Source comparison
PT-141 60s Age Specific Protocol: Dosing Comparison
Under 50 1.5–2mg 3–5 days 2.5–3mg Optional. Baseline only PDE5 inhibitors: 24-hour gap minimum Standard protocol suitable for most healthy adults with normal vascular function 50–59 1–1.5mg 5–7 days 2–2.25mg Recommended first 2 weeks PDE5 inhibitors: 36-hour g
This comparison does not assign a generated winner or score.
- Under 50
- 1.5–2mg
- 3–5 days
- 2.5–3mg
- Optional. Baseline only
- PDE5 inhibitors: 24-hour gap minimum
- Standard protocol suitable for most healthy adults with normal vascular function
- 50–59
- 1–1.5mg
- 5–7 days
- 2–2.25mg
- Recommended first 2 weeks
- PDE5 inhibitors: 36-hour gap; alpha-blockers: 24-hour gap
- Transitional range. Vascular changes beginning but not yet pronounced
- 60–69
- 0.5–1mg
- 7–10 days
- 1.5–1.75mg
- Required at every administration (first 2 hours)
- PDE5 inhibitors: 48–72 hour gap; alpha-blockers: 48-hour gap; anticoagulants: strict BP limits (<160 systolic)
- Age-specific adjustments essential. Reduced clearance and arterial compliance require lower starting doses and extended titration
- 70+
- 0.5mg
- 10–14 days
- 1.25–1.5mg
- Required at every administration (first 3 hours)
- PDE5 inhibitors: 72-hour minimum gap; alpha-blockers contraindicated same-week; anticoagulants: medical supervision required
- Highest-risk group for cardiovascular events. Conservative dosing mandatory, medical oversight recommended